RO7126209

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Alzheimers Disease

Phase 1

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

CompletedNCT04023994

Hoffmann-La RocheAlzheimers Disease

Start: 2019-08-03End: 2020-07-17Updated: 2021-08-09

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Active, not recruitingNCT04639050

Hoffmann-La RocheAlzheimers Disease

Start: 2021-03-15End: 2027-07-31Updated: 2026-09-14

Related Papers

Next wave of innovation in Alzheimer’s disease therapeutics: The value of novel active transport mechanisms

Alzheimer s & Dementia2025-12-01

Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease

Alzheimer s & Dementia2025-12-01

TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s disease

Alzheimer s & Dementia2025-12-01

Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s disease

Alzheimer s & Dementia2025-12-01

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease

JAMA Neurology2024-11-1827 citations

Early engagement with the wider patient community in early‐phase clinical trial design: Insights from the CareRing caregiver community in designing the Brainshuttle AD trial

Alzheimer s & Dementia2021-12-011 citations